No Data
No Data
Huibo Yuntong (301316.SZ): Plans to launch a restricted stock incentive plan for 3.99 million shares.
On February 13, Glonghui announced that Huibo Yuntong (301316.SZ) has disclosed its restricted stock incentive plan for 2025. The total number of restricted stocks to be granted under this incentive plan (Category 1 restricted stocks) is 3.99 million shares, accounting for approximately 1.00% of the total share capital of the company at the time of the announcement of the draft incentive plan. A total of 81 individuals will be granted the restricted stocks under this incentive plan at a grant price of 12.65 yuan per share.
Huibo Yuntong (301316.SZ): Currently not involved in the research and development of AI large models.
On February 12, Gelonghui reported that Huibo Yuntong (301316.SZ) stated on the investor interaction platform that the company is not currently involved in the research and development of large AI models. The company can provide customers with customized services for enterprise generative AI models and one-stop AI application development services. The reduction in shareholding by major shareholders is due to their own funding needs, and the company is currently operating normally.
Is Hydsoft TechnologyLtd (SZSE:301316) A Risky Investment?
Declining Stock and Solid Fundamentals: Is The Market Wrong About Hydsoft Technology Co.,Ltd. (SZSE:301316)?
Huibo Yuntong (301316.SZ): Providing Information Technology Services for clients such as CHINA MOBILE, Xiaomi, Huawei, and LM Ericsson Telephone in the field of 5G.
On December 24, Glonghui reported that Huibo Yuntong (301316.SZ) stated on the investor interaction platform that the company provides Information Technology Services for customers such as CHINA MOBILE, Xiaomi, Huawei, and LM Ericsson Telephone in the field of 5G.
Huibot Cloud (301316.SZ): Can provide AI smart assistants for Medical Industry clients based on natural language processing AI technology.
On December 24, Gelonghui reported that Huibo Yuntong (301316.SZ) stated on the investor interaction platform that the company can provide AI intelligent assistants for clients in the Medical Industry based on natural language processing AI technology.